Gastro hep advances最新文献

{"title":"Assessing Aberrant Subclavian Artery on High-Resolution Esophageal Manometry","authors":"Lauren Loeb, Manar Al Jawish, Andree H. Koop","doi":"10.1016/j.gastha.2024.10.010","DOIUrl":"10.1016/j.gastha.2024.10.010","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 2","pages":"Article 100570"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover: Adenosine Receptor 3 in Liver Cancer","authors":"","doi":"10.1016/S2772-5723(25)00037-8","DOIUrl":"10.1016/S2772-5723(25)00037-8","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 3","pages":"Article 100650"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LincPRKD: A Long Intergenic Noncoding RNA Activated in Gastric Cancer","authors":"Durgadevi Ravillah , Komal Keerthy , Salendra Singh , Adam Kresak , Kishore Guda , Andrew E. Blum","doi":"10.1016/j.gastha.2025.100618","DOIUrl":"10.1016/j.gastha.2025.100618","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 5","pages":"Article 100618"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Differences in Colonic Inflammation are Driven by Epithelial-Specific Expression of Estrogen Receptor Alpha","authors":"Guillermo A. Pereda ,&nbsp;Adrian D. Kocinski ,&nbsp;Alyssia V. Broncano ,&nbsp;Sarah K. McNeer ,&nbsp;Michelle L. Raymond ,&nbsp;Nicholas P. Ziats ,&nbsp;Keith A. Breau ,&nbsp;Joseph Burclaff ,&nbsp;Scott T. Magness ,&nbsp;Wendy A. Goodman","doi":"10.1016/j.gastha.2025.100624","DOIUrl":"10.1016/j.gastha.2025.100624","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Inflammatory bowel disease patients exhibit altered expression of nuclear estrogen receptors alpha and beta (ERα and ERβ) and G-protein coupled estrogen receptor 1 (GPER1). We previously showed that deletion of ERα protects against intestinal damage selectively in female mice; however, the mechanisms conferring sex-specific protection are poorly understood. The goal of this study was to compare ERα- and ERβ-specific mechanisms contributing to intestinal epithelial function in males and females.</div></div><div><h3>Methods</h3><div>Expression of ERα, ERβ, and GPER1 was evaluated in colonocytes from wild-type male and female mice. Intestinal epithelial cell (IEC)-specific ERα and ERβ knockout mice were developed and challenged with dextran sulfate sodium. Colonic organoids were used to identify estrogen-dependent and estrogen-independent effects on cellular growth, differentiation, and transcriptional regulation in wild-type, ERα-KO, and ERβ-KO IECs.</div></div><div><h3>Results</h3><div>Colonic IECs showed significant expression of ERα, ERβ, and GPER1 as well as Cyp19A1, which catalyzes production of 17β-estradiol (estrogen). Female mice lacking ERα specifically in colonic IECs showed protection from dextran sulfate sodium–induced injury, whereas males showed increased pathology. Organoids derived from male ERα-KO mice showed enhanced proliferation and decreased expression of key functional genes even without exogenous estrogen; however, colonoids derived from female ERα-KO mice showed a protective gene signature. These findings reveal that deletion of ERα contributes to differential effects in male and female IECs, contributing to females’ resistance to intestinal injury and inflammation.</div></div><div><h3>Conclusion</h3><div>ERα signaling within IECs drives opposing sex-dependent effects on the development, regenerative capacity, and inflammatory susceptibility of the intestinal epithelium.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 5","pages":"Article 100624"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143843594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thiamine-Reduced Fatigue in Quiescent Inflammatory Bowel Disease Is Linked to Faecalibacterium prausnitzii Abundance","authors":"Sandra Bermúdez-Sánchez ,&nbsp;Palle Bager ,&nbsp;Jens Frederik Dahlerup ,&nbsp;Simon Mark Dahl Baunwall ,&nbsp;Tine Rask Licht ,&nbsp;Martin Steen Mortensen ,&nbsp;Christian Lodberg Hvas","doi":"10.1016/j.gastha.2024.08.012","DOIUrl":"10.1016/j.gastha.2024.08.012","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Chronic fatigue is common in patients with inflammatory bowel disease (IBD). The gut microbiota, specifically, microbial diversity and butyrate-producing bacteria have been linked to the fatigue pathogenesis. High-dose oral thiamine reduces fatigue, potentially through gut microbiota modification. In this study, we investigated how the gut microbiota influences the efficacy of high-dose thiamine in alleviating chronic fatigue in quiescent IBD (qIBD).</div></div><div><h3>Methods</h3><div>We analyzed the microbiota and short-chain fatty acids concentrations in fecal samples from patients with qIBD, with (n = 40) or without (n = 20) chronic fatigue. The 40 patients with qIBD and fatigue were included in a randomized, placebo-controlled, crossover trial to assess a 4-week high-oral-dose thiamine regimen.</div></div><div><h3>Results</h3><div>Butyrate and butyrate-producing bacteria were similar in patients with and without fatigue and did not change with high-dose thiamine treatment. Notably, <em>Faecalibacterium prausnitzii</em> was more abundant in thiamine responders compared with nonresponders both pretreatment (<em>P</em> = .019) and post-treatment (<em>P</em> = .038). The relative abundances of <em>Faecalibacterium prausnitzii</em> and <em>Roseburia hominis</em>, both pretreatment and post-treatment, inversely correlated with IBD fatigue score changes for patients with chronic fatigue (PRE; R = −0.48, <em>P</em> = .004, and R = −0.40, <em>P</em> = .018; POST; R = −0.42, <em>P</em> = .012, and R = −0.40, <em>P</em> = .017) respectively.</div></div><div><h3>Conclusion</h3><div><em>Faecalibacterium prausnitzii</em> and <em>Roseburia hominis</em> may serve as markers for response to high-dose thiamine in alleviating chronic fatigue in patients with qIBD. The mechanistic role of gut bacteria and butyrate in patients with chronic fatigue and qIBD should be further explored.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 1","pages":"Article 100533"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11713491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease","authors":"Brian G. Feagan ,&nbsp;Jean-Frederic Colombel ,&nbsp;Remo Panaccione ,&nbsp;Stefan Schreiber ,&nbsp;Marc Ferrante ,&nbsp;Koji Kamikozuru ,&nbsp;Christopher Ma ,&nbsp;Wan-Ju Lee ,&nbsp;Jenny Griffith ,&nbsp;Namita Joshi ,&nbsp;Kristina Kligys ,&nbsp;Jasmina Kalabic ,&nbsp;Si Xuan ,&nbsp;Marla Dubinsky","doi":"10.1016/j.gastha.2024.08.022","DOIUrl":"10.1016/j.gastha.2024.08.022","url":null,"abstract":"<div><h3>Background and Aims</h3><div>We evaluated the association between endoscopic outcomes following risankizumab induction and subsequent rates of hospitalization and surgery through 52 weeks of risankizumab (both doses) maintenance therapy in patients with Crohn’s disease (CD).</div></div><div><h3>Methods</h3><div>Patients with moderately to severely active CD and clinical response to 12-week risankizumab induction were rerandomized to continued therapy or drug withdrawal in the phase 3 FORTIFY maintenance trial. Incidence rates (events/100 person-years) of CD-related hospitalization and surgery, and the composite of both, through 52 weeks of maintenance were compared between patients achieving vs not achieving predefined endoscopic outcomes following induction.</div></div><div><h3>Results</h3><div>Patients who achieved vs did not achieve endoscopic response or remission, or absence of ulcers (ulcer-free endoscopy) after induction had reduced rates of CD-related hospitalization through 52 weeks of risankizumab maintenance (endoscopic response, 1.7 vs 7.9/100 person-years; endoscopic remission, 1.2 vs 6.9/100 person-years; ulcer-free endoscopy, 1.5 vs 6.4/100 person-years; all <em>P</em> &lt; .05). No CD-related surgeries were observed through 52 weeks of risankizumab maintenance among patients who achieved vs did not achieve endoscopic outcomes following induction (endoscopic response, 0 vs 3.2/100 person-years; endoscopic remission, 0 vs 2.6/100 person-years; ulcer-free endoscopy, 0 vs 2.4/100 person-years; all <em>P</em> = .025). In contrast, patients who received placebo during maintenance had statistically similar rates of CD-related hospitalizations and surgeries regardless of achievement of endoscopic outcomes after induction.</div></div><div><h3>Conclusion</h3><div>Patients achieving endoscopic outcomes following risankizumab induction experienced less CD-related hospitalizations and surgeries through 52 weeks of maintenance when continuing active therapy. Early treatment success may predict favorable long-term outcomes of disease.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 1","pages":"Article 100544"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric Ischemia From Partial Dual-Vessel Occlusion","authors":"Fangfang Wang ,&nbsp;Amani Elshaer ,&nbsp;Vijay P. Singh","doi":"10.1016/j.gastha.2024.10.013","DOIUrl":"10.1016/j.gastha.2024.10.013","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 3","pages":"Article 100573"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease","authors":"Brian G. Feagan ,&nbsp;Remo Panaccione ,&nbsp;Stefan Schreiber ,&nbsp;Edward V. Loftus Jr. ,&nbsp;Laurent Peyrin-Biroulet ,&nbsp;Takehiro Arai ,&nbsp;Wan-Ju Lee ,&nbsp;Jenny Griffith ,&nbsp;Jasmina Kalabic ,&nbsp;Kristina Kligys ,&nbsp;Si Xuan ,&nbsp;Xiaomei Liao ,&nbsp;Marc Ferrante","doi":"10.1016/j.gastha.2024.100603","DOIUrl":"10.1016/j.gastha.2024.100603","url":null,"abstract":"<div><h3>Background and Aims</h3><div>In phase 3 induction (ADVANCE and MOTIVATE) and maintenance (FORTIFY) trials, risankizumab was shown to benefit symptom and endoscopic defined outcomes in patients with Crohn’s disease (CD). We examined the effects of risankizumab on the incidence of CD-related hospitalizations in these studies.</div></div><div><h3>Methods</h3><div>Patients with active CD were randomized to intravenous (IV) risankizumab 600 or 1200 mg, or placebo at weeks 0, 4, and 8 in the 12-week induction studies. Clinical responders were rerandomized to maintenance with subcutaneous (SC) risankizumab 180 or 360 mg or placebo every 8 weeks for 52 weeks. Incidence of CD-related hospitalizations was compared between groups, expressed as proportions with an event during induction and event/100 person-years (PYs) during maintenance. An integrated analysis incorporated exposure time and occurrence of CD-related hospitalizations in induction and maintenance periods for labeled doses.</div></div><div><h3>Results</h3><div>The incidence of CD-related hospitalizations was lower (3.2% or 1.9% vs 11.6%; <em>P</em> &lt; .01) in the risankizumab IV 600- and 1200-mg groups vs placebo IV during induction. Through 52 weeks, the incidence rate per 100 PYs of CD-related hospitalizations was similar among treatment groups, with few events reported (n = 5–9 per group). In the integrated analysis, a lower incidence rate per 100 PYs of CD-related hospitalizations was observed in the risankizumab-treated groups (600 mg IV/360 mg SC: 9.6; 600 mg IV/180 mg SC: 7.9) vs placebo (40.0, <em>P</em> &lt; .001).</div></div><div><h3>Conclusion</h3><div>Risankizumab treatment resulted in reduced rates of CD-related hospitalization with treatment effect observed within 12 weeks of randomization.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 4","pages":"Article 100603"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143643072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Outcomes of Endoscopic Ultrasound-Guided Pancreatic Cyst Ablation: A Systematic Review and Meta-Analysis","authors":"Ahmed Al Qady ,&nbsp;Kapil Dev Nayar ,&nbsp;Fatima Elmustafa ,&nbsp;Mohamed Salih ,&nbsp;Joseph Emran ,&nbsp;Amir Beirat ,&nbsp;Sasmith Menakuru ,&nbsp;Dana Harris ,&nbsp;Dan J. Echols ,&nbsp;Baoan Ji ,&nbsp;John M. DeWitt ,&nbsp;Zhen Wang ,&nbsp;Fernando F. Stancampiano ,&nbsp;Yan Bi","doi":"10.1016/j.gastha.2024.100595","DOIUrl":"10.1016/j.gastha.2024.100595","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Pancreatic cysts (PCs) are increasingly detected through abdominal imaging, prompting exploration of alternatives such as endoscopic ultrasound–guided PC ablation due to the risks and costs associated with surgery. This study conducts a systematic review and meta-analysis of endoscopic ultrasound–guided PC ablation’s short-term efficacy and complications for PC management.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis were carried out on PubMed, Ovid, Cochrane, and TRIP electronic databases. The primary outcome was cyst resolution (partial and complete) and persistence on imaging 12 months after ablation. The secondary outcome was procedure-related adverse events.</div></div><div><h3>Results</h3><div>Eight studies were eligible for analysis. Complete cyst resolution on imaging 12 months after endoscopic ultrasound ablation was 50% [95% CI 36‒63, I2 = 85.31%]. Partial cyst resolution was 27% [95% CI 15‒41, I2 = 87.07%], and cyst persistence was 17% [95% CI 11‒24, I2 = 62.11%]. The rate of complete resolution varied depending on the treatment agent (for ethanol 29% [95% CI 10‒53]; lauromacrogol 51% [95% Cl 36‒67]; ethanol and paclitaxel 63% [95% CI 48‒76]; paclitaxel and gemcitabine 67% [95% CI 45‒83]; and ethanol, paclitaxel, and gemcitabine 61% [95% CI 39‒80]). Postprocedure adverse events included abdominal pain in 4% [95% CI 0‒11], pancreatitis in 3% [95% CI 1‒5], and fever in 1% [95% CI 0‒3] of all patients.</div></div><div><h3>Conclusion</h3><div>The treatment of pancreatic cysts with endoscopic ultrasound ablation results in acceptable levels of complete resolution, and low incidence of severe adverse events. The effectiveness of this treatment is further enhanced when chemoablative agents are employed.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 4","pages":"Article 100595"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143237194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colonic Intussusception Following Colonoscopy: A Case Report and Literature Review","authors":"Faisal Mehmood ,&nbsp;Hajra Jamil ,&nbsp;Shreya Amin ,&nbsp;Joseph Fares ,&nbsp;Mehul Patel","doi":"10.1016/j.gastha.2024.100612","DOIUrl":"10.1016/j.gastha.2024.100612","url":null,"abstract":"<div><div>Intussusception following a colonoscopy is a rare complication, potentially triggered by biopsies or polypectomies. The most common symptoms include abdominal pain, nausea, vomiting, hematochezia, and fever. A computed tomography scan is the most sensitive diagnostic tool for detecting intussusception. While management is usually conservative, surgery may be required in rare instances. Only 13 cases of colo-colonic intussusception following colonoscopy have been reported, and among those, 4 needed a surgical intervention. We present a case of an elderly male who developed colo-colonic intussusception requiring a hemicolectomy after undergoing a colonoscopy with polypectomy.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 5","pages":"Article 100612"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}